Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Dave Roman | Goldman Sachs | 12 | 8% |
| Vijay Kumar | Evercore ISI | 12 | 25% |
| Travis Steed | Bank of America | 12 | 17% |
| Robbie Marcus | JPMorgan | 12 | 8% |
| Larry Biegelsen | Wells Fargo | 12 | 17% |
| Matt Taylor | Jefferies | 7 | 0% |
| Matt Miksic | Barclays | 5 | 0% |
| Joanne Wuensch | Citigroup | 4 | 0% |
| Pito Chickering | Deutsche Bank | 4 | 0% |
| Chris Pasquale | Nephron Research | 3 | 33% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Bank of America | 1 | 12 | 17% |
| Evercore ISI | 1 | 12 | 25% |
| Goldman Sachs | 1 | 12 | 8% |
| JPMorgan | 1 |
| 12 |
| 8% |
| Wells Fargo | 1 | 12 | 17% |
| Jefferies | 1 | 7 | 0% |
| Barclays | 1 | 5 | 0% |
| Deutsche Bank | 1 | 4 | 0% |
Edwards Lifesciences opened FY2026 with reported sales of $1.65 billion, up 12.7% on an underlying basis (about 16.7% as reported, aided by roughly 400 basis points of favorable foreign exchange), with broad-based strength across TAVR, TMTT, and Surgical. TAVR sales rose 11% to $1.2 billion on renewed clinical focus and long-term SAPIEN durability evidence, while TMTT surged approximately 42% to $173 million on EVOQUE, PASCAL, and the new SAPIEN M3. Adjusted EPS of $0.78 beat expectations and adjusted operating profit margin reached 31.4%, reflecting operating leverage and planned phasing of strategic investments, while GAAP EPS was $0.66. On the back of the Q1 outperformance, management raised full-year sales-growth guidance to 9%-11% and adjusted EPS guidance to $2.95-$3.05, and pointed to potential reimbursement tailwinds from the CMS TAVR NCD reconsideration and the new RAPID breakthrough-therapy policy.
Demand | Innovation & R&D | Product Launch | Competitive Dynamics | Revenue Growth | Regulation Policy | Guidance Reliability | Margin | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 7 | 4 | 9 | 1 | 7 | 2 | 4 | 1 |
| 2025Q1 | 7 | 4 | 5 | 4 | 4 | 6 | 2 | 3 |
| 2025Q2 | 6 | 3 | 3 | 4 | 1 | 3 | 4 | 5 |
| 2025Q3 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 3 |
| 2025Q4 | 6 | 5 | 2 | 3 | 4 | 2 | 1 | 1 |
| 2026Q1 | 2 | 3 | 3 | 6 | 1 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 7 | 7 | 6 | 6 | 6 | 2 |
| Innovation & R&D | 4 | 4 | 3 | 6 | 5 | 3 |
| Product Launch | 9 | 5 | 3 | 2 | 2 | 3 |
| Competitive Dynamics | 1 | 4 | 4 | 2 | 3 | 6 |
| Revenue Growth | 7 | 4 | 1 | 1 | 4 | 1 |
| Regulation Policy | 2 | 6 | 3 | 2 | 2 | 2 |
| Guidance Reliability | 4 | 2 | 4 | 1 | 1 | 3 |
| Margin | 1 | 3 | 5 | 3 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
EW Edwards Lifesciences | 9 | +16.7% | |
| ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| STE Steris | 7 | +7.3% | |
| SYK Stryker Corporation | 4 | +2.6% | |
| ZBH Zimmer Biomet | 9 | +9.3% |